Abstract
Forty-six patients with chronic myeloid leukemia receiving imatinib mesylate (39 in chronic phase, one in accelerated phase, and six in blastic crisis), were studied for a 20-62 month follow-up period by cytogenetics and fluorescence in situ hybridization using dual-color, dual-fusion BCR and ABL probes. This approach provided valuable results for disease management of analysis.
Publication types
-
Letter
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Benzamides
-
Chromosome Deletion*
-
Chromosomes, Human, Pair 9
-
Follow-Up Studies
-
Humans
-
Imatinib Mesylate
-
In Situ Hybridization, Fluorescence
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / diagnosis*
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
-
Neoplasm, Residual / diagnosis
-
Neoplasm, Residual / genetics
-
Piperazines / therapeutic use*
-
Pyrimidines / therapeutic use*
Substances
-
Benzamides
-
Piperazines
-
Pyrimidines
-
Imatinib Mesylate